1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/21789
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorGogas, H.en
dc.contributor.authorDafni, U.en
dc.contributor.authorBourli, A.en
dc.contributor.authorFillipidis, T.en
dc.contributor.authorSotiropoulou, M.en
dc.contributor.authorVlachodimitropoulos, D.en
dc.contributor.authorPapadopoulos, S.en
dc.contributor.authorTzaida, O.en
dc.contributor.authorKafiri, G.en
dc.contributor.authorKyriakou, V.en
dc.contributor.authorMarkaki, S.en
dc.contributor.authorPapaspyrou, I.en
dc.contributor.authorKaragianni, E.en
dc.contributor.authorPavlakis, K.en
dc.contributor.authorToliou, T.en
dc.contributor.authorScopa, C.en
dc.contributor.authorPapakostas, P.en
dc.contributor.authorBafaloukos, D.en
dc.contributor.authorChristodoulou, C.en
dc.contributor.authorFountzilas, G.en
dc.date.accessioned2015-11-24T19:17:33Z-
dc.date.available2015-11-24T19:17:33Z-
dc.identifier.issn0923-7534-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/21789-
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/administration &en
dc.subjectdosage/*therapeutic useen
dc.subjectBreast Neoplasms/*diagnosis/drug therapy/metabolism/mortality/pathologyen
dc.subjectCarcinoma, Ductal, Breast/*diagnosis/drug therapy/metabolism/mortality/pathologyen
dc.subjectChemotherapy, Adjuvanten
dc.subjectCyclophosphamide/administration & dosageen
dc.subjectDose-Response Relationship, Drugen
dc.subjectEpirubicin/administration & dosageen
dc.subjectFemaleen
dc.subjectFluorouracil/administration & dosageen
dc.subjectGene Expressionen
dc.subjectHumansen
dc.subjectMethotrexate/administration & dosageen
dc.subjectMiddle Ageden
dc.subjectMolecular Diagnostic Techniques/methodsen
dc.subjectPaclitaxel/administration & dosageen
dc.subjectPredictive Value of Testsen
dc.subjectPrognosisen
dc.subjectProto-Oncogene Proteins c-bcl-2/*metabolismen
dc.subjectSurvival Analysisen
dc.subjectTumor Markers, Biological/metabolismen
dc.subjectTumor Suppressor Protein p53/*metabolismen
dc.titleEvaluation of the prognostic and predictive value of p53 and Bcl-2 in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapyen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1093/annonc/mdl147-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16968874-
heal.identifier.secondaryhttp://annonc.oxfordjournals.org/content/17/10/1504.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2006-
heal.abstractPURPOSE: To assess the prognostic and predictive significance of p53 and Bcl-2 protein expression in high risk patients with breast cancer treated with dose-dense sequential chemotherapy. PATIENTS AND METHODS: From June 1997 until November 2000, 595 patients were randomized to three cycles of epirubicin (E) 110 mg/m2 followed by three cycles of paclitaxel (P) 250 mg/m2 followed by three cycles of 'intensified' CMF (cyclophosphamide 840 mg/m2, methotrexate 47 mg/m2 and fluorouracil 840 mg/m2) or to four cycles of E, followed by four cycles of CMF. p53 and Bcl-2 expression was investigated by immunohistochemistry in 392 and 397 patients respectively. RESULTS: Positive expression of p53 was detected in 104 (26.5%) patients and was significantly associated with negative hormonal status, worse histologic grade, higher incidence of disease relapse and higher rate of death. p53 positive expression was a significant negative predictor of overall survival (OS) (P = 0.002) and disease-free survival (DFS) (P = 0.001). Negative expression of Bcl-2 was detected in 203 (51%) patients and was significantly associated with negative hormonal status. Multivariate analysis revealed that, positive p53 expression, higher number of positive nodes and worse tumor grade were related to significantly poorer OS and DFS. CONCLUSIONS: For both treatments, p53 positive expression was a significant negative prognostic factor for OS and DFS while Bcl-2 was not. No predictive ability of p53 status or Bcl-2 status for paclitaxel treatment was evident.en
heal.journalNameAnn Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Malamou-Mitsi-2006-Evaluation of the pr.pdf539.23 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons